Histone H3K27 dimethyl loss is highly specific for malignant peripheral nerve sheath tumor and distinguishes true PRC2 loss from isolated H3K27 trimethyl loss.
Journal
Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
ISSN: 1530-0285
Titre abrégé: Mod Pathol
Pays: United States
ID NLM: 8806605
Informations de publication
Date de publication:
10 2019
10 2019
Historique:
received:
07
02
2019
accepted:
04
04
2019
revised:
03
04
2019
pubmed:
9
6
2019
medline:
24
7
2020
entrez:
9
6
2019
Statut:
ppublish
Résumé
Malignant peripheral nerve sheath tumors contain loss of histone H3K27 trimethylation (H3K27me3) due to driver mutations affecting the polycomb repressive complex 2 (PRC2). Consequently, loss of H3K27me3 staining has served as a diagnostic marker for this tumor type. However, recent reports demonstrate H3K27me3 loss in numerous other tumors, including some in the differential diagnosis of malignant peripheral nerve sheath tumor. Since these tumors lose H3K27me3 through mechanisms distinct from PRC2 loss, we set out to determine whether loss of dimethylation of H3K27, which is also catalyzed by PRC2, might be a more specific marker of PRC2 loss and malignant peripheral nerve sheath tumor. Using mass spectrometry, we identify a near complete loss of H3K27me2 in malignant peripheral nerve sheath tumors and cell lines. Immunohistochemical analysis of 72 malignant peripheral nerve sheath tumors, seven K27M-mutant gliomas, 43 ependymomas, and 10 Merkel cell carcinomas demonstrates that while H3K27me3 loss is common across these tumor types, H3K27me2 loss is limited to malignant peripheral nerve sheath tumors and is highly concordant with H3K27me3 loss (33/34 cases). Thus, increased specificity does not come at the cost of greatly reduced sensitivity. To further compare H3K27me2 and H3K27me3 immunohistochemistry, we investigated 42 melanomas and 54 synovial sarcomas, histologic mimics of malignant peripheral nerve sheath tumor with varying degrees of H3K27me3 loss in prior reports. While global H3K27me3 loss was not seen in these tumors, weak and limited H3K27me3 staining was common. By contrast, H3K27me2 staining was more clearly retained in all cases, making it a superior binary classifier. This was confirmed by digital image analysis of stained slides. Our findings indicate that H3K27me2 loss is highly specific for PRC2 loss and that PRC2 loss is a rarer phenomenon than H3K27me3 loss. Consequently, H3K27me2 loss is a superior diagnostic marker for malignant peripheral nerve sheath tumor.
Identifiants
pubmed: 31175328
doi: 10.1038/s41379-019-0287-8
pii: S0893-3952(22)00998-X
pmc: PMC6763358
mid: NIHMS1526403
doi:
Substances chimiques
Biomarkers, Tumor
0
Histones
0
Polycomb Repressive Complex 2
EC 2.1.1.43
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1434-1446Subventions
Organisme : NIAID NIH HHS
ID : R01 AI118891
Pays : United States
Organisme : NCI NIH HHS
ID : P01 CA196539
Pays : United States
Organisme : NIGMS NIH HHS
ID : R01 GM110174
Pays : United States
Organisme : NCATS NIH HHS
ID : TL1 TR001880
Pays : United States
Organisme : NCI NIH HHS
ID : K12 CA076931
Pays : United States
Organisme : NIGMS NIH HHS
ID : T32 GM008275
Pays : United States
Références
Sci Transl Med. 2016 Nov 23;8(366):366ra161
pubmed: 27881822
Acta Neuropathol. 2018 Jun;135(6):955-963
pubmed: 29627952
Nat Genet. 2017 Feb;49(2):213-222
pubmed: 27941796
Cancer Cell. 2017 May 8;31(5):635-652.e6
pubmed: 28434841
Sci Rep. 2017 Dec 4;7(1):16878
pubmed: 29203879
Mod Pathol. 2019 Mar;32(3):435-445
pubmed: 30291346
Acta Neuropathol. 2017 Nov;134(5):705-714
pubmed: 28733933
Mod Pathol. 2019 Jan;32(Suppl 1):27-37
pubmed: 30600320
PLoS One. 2017 Aug 15;12(8):e0183155
pubmed: 28813519
Am J Surg Pathol. 2017 Mar;41(3):396-404
pubmed: 27849631
Proc Natl Acad Sci U S A. 2019 Mar 26;116(13):6075-6080
pubmed: 30867289
Am J Surg Pathol. 2016 Apr;40(4):479-89
pubmed: 26645727
Genes Dev. 2013 May 1;27(9):985-90
pubmed: 23603901
Methods Mol Biol. 2017;1528:121-148
pubmed: 27854019
Mod Pathol. 2016 Jan;29(1):4-13
pubmed: 26585554
Ann Surg. 2009 Jun;249(6):1014-22
pubmed: 19474676
Mol Cell. 2014 Jan 9;53(1):49-62
pubmed: 24289921
J Proteome Res. 2018 Jul 6;17(7):2533-2541
pubmed: 29790754
Nat Med. 2017 Apr;23(4):493-500
pubmed: 28263307
Science. 2013 May 17;340(6134):857-61
pubmed: 23539183
Mod Pathol. 2017 Dec;30(12):1710-1719
pubmed: 28776579
Science. 2016 Jun 3;352(6290):aad9780
pubmed: 27257261
Am J Surg Pathol. 2016 Jul;40(7):896-908
pubmed: 27158754
Anal Biochem. 1984 Apr;138(1):141-3
pubmed: 6731838
Acta Neuropathol. 2012 Mar;123(3):295-319
pubmed: 22327363
Cancer Res. 2019 Jul 1;79(13):3205-3219
pubmed: 30898839
Mol Cell. 2008 Nov 21;32(4):491-502
pubmed: 19026780
EMBO J. 2006 Jul 12;25(13):3110-22
pubmed: 16763550
Proteomics. 2015 Aug;15(15):2568-79
pubmed: 25825003
Nat Genet. 2014 Nov;46(11):1170-2
pubmed: 25305755
Nature. 2014 Oct 9;514(7521):247-51
pubmed: 25119042
Acta Neuropathol. 2018 Aug;136(2):211-226
pubmed: 29909548
Mod Pathol. 2016 Jun;29(6):582-90
pubmed: 26990975
Mod Pathol. 2017 Dec;30(12):1677-1687
pubmed: 28752843
Nat Genet. 2014 Nov;46(11):1227-32
pubmed: 25240281
Am J Surg Pathol. 2018 May;42(5):656-664
pubmed: 29309298
Histopathology. 2018 Jul;73(1):147-156
pubmed: 29489027
Sci Adv. 2018 Oct 31;4(10):eaau5935
pubmed: 30402543
Cancer Cell. 2013 Nov 11;24(5):660-72
pubmed: 24183680
Nat Med. 2017 Apr;23(4):483-492
pubmed: 28263309
Histopathology. 2017 Feb;70(3):385-393
pubmed: 27580378
Nucleic Acids Res. 2018 May 4;46(8):3817-3832
pubmed: 29618087
Epigenetics Chromatin. 2013 Jul 05;6(1):20
pubmed: 23826629
Pathol Res Pract. 2018 Mar;214(3):417-425
pubmed: 29482987
Mod Pathol. 2017 Jun;30(6):877-883
pubmed: 28281550
Mol Cell. 2003 Dec;12(6):1577-89
pubmed: 14690609
PLoS Genet. 2016 Jul 14;12(7):e1006151
pubmed: 27414999
Nat Med. 2015 Jun;21(6):555-9
pubmed: 25939062
EMBO J. 2004 Oct 13;23(20):4061-71
pubmed: 15385962